Precision medicine in cardiac electrophysiology: where we are and where we need to go

References

• Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med [Internet]. 1991 Mar 21;324(12):781–788.
   PubMed Web of Science ®Google Scholar
• Køber L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med [Internet]. 2008 Jun 19;358(25):2678–2687.
   PubMed Web of Science ®Google Scholar
• Kober L, Bloch Thomsen PE, Moller M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet. 2000 Dec;356(9247):2052–2058.
   PubMed Web of Science ®Google Scholar
• Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD investigators. Survival with oral d-sotalol. Lancet. 1996 Jul;348(9019):7–12.
   PubMed Web of Science ®Google Scholar
• Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter. Circulation. 2000;102(19):2385–2390.
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish investigations of arrhythmia and mortality on dofetilide study group. N Engl J Med. 1999 Sep;341(12):857–865.
   PubMed Web of Science ®Google Scholar
• Antiarryhthmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997 Nov;337(22);1576–1583.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002 Mar;346(12):877–883.
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan;352(3):225–237.
   PubMed Web of Science ®Google Scholar
• Pappone C, Vicedomini G, Augello G, et al. Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4-year follow-up trial: the APAF study. Circ Arrhythm Electrophysiol. 2011 Dec;4(6):808–814.
   PubMed Web of Science ®Google Scholar
• Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012 Oct;367(17):1587–1595.
   PubMed Web of Science ®Google Scholar
• Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014 Feb;311(7):692–700.
   PubMed Web of Science ®Google Scholar
• Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med [Internet]. 2018 Jan 31;378(5):417–427.
   PubMed Web of Science ®Google Scholar
• Roden DM. Personalized medicine to treat arrhythmias. Curr Opin Pharmacol. 2014 Apr;15:61–67.
   PubMed Web of Science ®Google Scholar
• Zhu M, Zhao S. Candidate gene identification approach: progress and challenges. Int J Biol Sci. 2007 Oct;3(7):420–427.
   PubMed Web of Science ®Google Scholar
• Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet England. 2002;3:391–397.
   PubMed Web of Science ®Google Scholar
• Farrell MS, Werge T, Sklar P, et al. Evaluating historical candidate genes for schizophrenia. Mol Psychiatry. 2015 May;20(5):555–562.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA. 2008 Mar;299(11):1335–1344.
   PubMed Web of Science ®Google Scholar
• Pulst SM. Genetic linkage analysis. Arch Neurol. 1999 Jun;56(6):667–672.
   PubMedGoogle Scholar
• Brenyo AJ, Huang DT, Aktas MK. Congenital long and short QT syndromes. Cardiology. 2012;122(4):237–247.
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Crotti L, Insolia R. Long-QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol. 2012 Aug;5(4):868–877.
   PubMed Web of Science ®Google Scholar
• Romano C, Gemme G, Pongiglione R. Rare cardiac arrythmias of the pediatric age. II. Syncopal attacks due to paroxysmal ventricular fibrillation. (Presentation of 1st case in Italian pediatric literature). Clin Pediatr (Bologna). 1963 Sep;45:656–683.
   PubMedGoogle Scholar
• Ward OC. A new familial cardiac syndrome in children. J Ir Med Assoc. 1964 Apr;54:103–106.
   PubMedGoogle Scholar
• Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J. 1957 Jul;54(1):59–68.
   PubMed Web of Science ®Google Scholar
• Andersen ED, Krasilnikoff PA, Overvad H. Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies. A new syndrome? Acta Paediatr Scand. 1971 Sep;60(5):559–564.
   PubMed Web of Science ®Google Scholar
• Tawil R, Ptacek LJ, Pavlakis SG, et al. Andersen’s syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol. 1994 Mar;35(3):326–330.
   PubMed Web of Science ®Google Scholar
• Splawski I, Timothy KW, Decher N, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci U S A. 2005 Jun;102(23):8088–8089.
   Web of Science ®Google Scholar
• Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996 Jan;12(1):17–23.
   PubMed Web of Science ®Google Scholar
• Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995 Mar;80(5):795–803.
   PubMed Web of Science ®Google Scholar
• Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995 Mar;80(5):805–811.
   PubMed Web of Science ®Google Scholar
• Keating M, Atkinson D, Dunn C, et al. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science. 1991 May;252(5006):704–706.
   PubMed Web of Science ®Google Scholar
• Towbin JA, Li H, Taggart RT, et al. Evidence of genetic heterogeneity in Romano-Ward long QT syndrome. Analysis of 23 families. Circulation. 1994 Dec;90(6):2635–2644.
   PubMed Web of Science ®Google Scholar
• Dausse E, Denjoy I, Kahlem P, et al. Readjusting the localization of long QT syndrome gene on chromosome 11p15. C R Acad Sci III. 1995 Aug;318(8):879–885.
   PubMed Web of Science ®Google Scholar
• Jiang C, Atkinson D, Towbin JA, et al. Two long QT syndrome loci map to chromosomes 3 and 7 with evidence for further heterogeneity. Nat Genet. 1994 Oct;8(2):141–147.
   PubMed Web of Science ®Google Scholar
• Tyson J, Tranebjaerg L, Bellman S, et al. IsK and KvLQT1: mutation in either of the two subunits of the slow component of the delayed rectifier potassium channel can cause Jervell and Lange-Nielsen syndrome. Hum Mol Genet. 1997 Nov;6(12):2179–2185.
   PubMed Web of Science ®Google Scholar
• Schulze-Bahr E, Wang Q, Wedekind H, et al. KCNE1 mutations cause jervell and Lange-Nielsen syndrome. Nat Genet. 1997;17:267–268. United States.
   PubMed Web of Science ®Google Scholar
• Adler A, Novelli V, Amin AS, et al. An international, multicentered, evidence-based reappraisal of genes reported to cause congenital long QT syndrome. Circulation. 2020 Feb;141(6):418–428.
   PubMed Web of Science ®Google Scholar
• Brink PA, Lia C, Valerie C, et al. Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. Circulation [Internet]. 2005 Oct 25;112(17):2602–2610.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Wojciech Z, Kaufman ES, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the Pore region of the human ether-a-go-go–related gene potassium channel. Circulation [Internet]. 2002 Feb 19;105(7):794–799.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Wataru S, Wilde AAM, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation [Internet]. 2007 May 15;115(19):2481–2489.
   PubMed Web of Science ®Google Scholar
• Crotti L, Lundquist AL, Insolia R, et al. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation. 2005 Aug;112(9):1251–1258.
   PubMed Web of Science ®Google Scholar
• Duchatelet S, Crotti L, Peat RA, et al. Identification of a KCNQ1 polymorphism acting as a protective modifier against arrhythmic risk in long-QT syndrome. Circ Cardiovasc Genet. 2013 Aug;6(4):354–361.
   PubMedGoogle Scholar
• Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001 Jan;103(1):89–95.
   PubMed Web of Science ®Google Scholar
• Martini B, Nava A, Thiene G, et al. Ventricular fibrillation without apparent heart disease: description of six cases. Am Heart J. 1989 Dec;118(6):1203–1209.
   PubMed Web of Science ®Google Scholar
• Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter report. J Am Coll Cardiol [Internet]. 1992;20(6):1391–1396. Available from: http://www.sciencedirect.com/science/article/pii/073510979290253J
   PubMed Web of Science ®Google Scholar
• Brugada J, Campuzano O, Arbelo E, et al. Present status of brugada syndrome: JACC state-of-the-art review. J Am Coll Cardiol. 2018 Aug;72(9):1046–1059.
   PubMed Web of Science ®Google Scholar
• de Luna AB, Brugada J, Baranchuk A, et al. Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol [Internet]. 2012;45(5):433–442. Available from: http://www.sciencedirect.com/science/article/pii/S0022073612002026
   PubMed Web of Science ®Google Scholar
• Casado-Arroyo R, Berne P, Rao JY, et al. Long-term trends in newly diagnosed brugada syndrome: implications for risk stratification. J Am Coll Cardiol. 2016 Aug;68(6):614–623.
   PubMed Web of Science ®Google Scholar
• Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998 Mar;392(6673):293–296.
   PubMed Web of Science ®Google Scholar
• Hosseini SM, Kim R, Udupa S, et al. Reappraisal of reported genes for sudden arrhythmic death. Circulation. 2018 Sep;138(12):1195–1205.
   PubMed Web of Science ®Google Scholar
• Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Hear Rhythm. 2010 Jan;7(1):33–46.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C. Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2024–38.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C. Drug-induced spatial dispersion of repolarization. Cardiol J. 2008;15(2):100–121.
   PubMedGoogle Scholar
• Bezzina C, Veldkamp MW, van Den Berg MP, et al. A single Na(+) channel mutation causing both long-QT and Brugada syndromes. Circ Res. 1999 Dec;85(12):1206–1213.
   PubMed Web of Science ®Google Scholar
• Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation. 1999 Oct;100(15):1660–1666.
   PubMed Web of Science ®Google Scholar
• Mok N-S, Priori SG, Napolitano C, et al. A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia. J Cardiovasc Electrophysiol. 2003 Apr;14(4):407–411.
   PubMed Web of Science ®Google Scholar
• Porres JM, Brugada J, Urbistondo V, et al. Fever unmasking the Brugada syndrome. Pacing Clin Electrophysiol. 2002 Nov;25(11):1646–1648.
   PubMed Web of Science ®Google Scholar
• Amin AS, Meregalli PG, Bardai A, et al. Fever increases the risk for cardiac arrest in the Brugada syndrome. Ann Intern Med United States. 2008;149:216–218.
   PubMed Web of Science ®Google Scholar
• Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Hear Rhythm. 2013 Dec;10(12):1932–1963.
   PubMed Web of Science ®Google Scholar
• Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015 Nov;36(41):2793–2867.
   PubMed Web of Science ®Google Scholar
• Bhuiyan ZA, van den Berg MP, van Tintelen JP, et al. Expanding spectrum of human RYR2-related disease. Circulation. 2007;116(14):1569–1576.
   PubMed Web of Science ®Google Scholar
• Swan H, Piippo K, Viitasalo M, et al. Arrhythmic disorder mapped to chromosome 1q42–q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol [Internet]. 1999;34(7):2035–2042. Available from: http://www.sciencedirect.com/science/article/pii/S0735109799004611
   PubMed Web of Science ®Google Scholar
• Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103(2):196–200.
   PubMed Web of Science ®Google Scholar
• Laitinen PJ, Brown KM, Piippo K, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation. 2001;103(4):485–490.
   PubMed Web of Science ®Google Scholar
• Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, et al. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol [Internet]. 2009;54(22):2065–2074. Available from: http://www.sciencedirect.com/science/article/pii/S0735109709029350
   PubMed Web of Science ®Google Scholar
• Lahat H, Eldar M, Levy-Nissenbaum E, et al. Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia. Circulation. 2001;103(23):2822–2827.
   PubMed Web of Science ®Google Scholar
• Campuzano O, Sarquella-Brugada G, Brugada R, et al. Genetics of channelopathies associated with sudden cardiac death. Glob Cardiol Sci Pract. 2015;2015(3):39.
   PubMedGoogle Scholar
• Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation. 2004;109(1):30–35.
   PubMed Web of Science ®Google Scholar
• Hong KUI, Bjerregaard P, Gussak I, et al. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol [Internet]. 2005;16(4):394–396. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1540-8167.2005.40621.x
   PubMed Web of Science ®Google Scholar
• Bellocq C, van Ginneken ACG, Bezzina CR, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation. 2004;109(20):2394–2397.
   PubMed Web of Science ®Google Scholar
• Hong K, Piper DR, Diaz-Valdecantos A, et al. De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. Cardiovasc Res [Internet]. 2005;68(3):433–440.
   PubMed Web of Science ®Google Scholar
• Moreno C, Oliveras A, de la Cruz A, et al. A new KCNQ1 mutation at the S5 segment that impairs its association with KCNE1 is responsible for short QT syndrome. Cardiovasc Res [Internet]. 2015;107(4):613–623.
   PubMed Web of Science ®Google Scholar
• Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res. 2005;96(7):800–807.
   PubMed Web of Science ®Google Scholar
• Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature. 2007 Jul;448(7151):353–357.
   PubMed Web of Science ®Google Scholar
• Kaab S, Darbar D, van Noord C, et al. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J. 2009 Apr;30(7):813–819.
   PubMed Web of Science ®Google Scholar
• Wang J, Klysik E, Sood S, et al. Pitx2 prevents susceptibility to atrial arrhythmias by inhibiting left-sided pacemaker specification. Proc Natl Acad Sci U S A. 2010 May;107(21):9753–9758.
   PubMed Web of Science ®Google Scholar
• Parvez B, Vaglio J, Rowan S, et al. Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation. J Am Coll Cardiol [Internet]. 2012;60(6):539–545. Available from: http://www.onlinejacc.org/content/60/6/539
   PubMed Web of Science ®Google Scholar
• Hodgson-Zingman DM, Karst ML, Zingman LV, et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med. 2008 Jul;359(2):158–165.
   PubMed Web of Science ®Google Scholar
• Yang T, Yang P, Roden DM, et al. Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. Hear Rhythm. 2010 Sep;7(9):1246–1252.
   PubMed Web of Science ®Google Scholar
• Filonenko K, Katus HA, Meder B. Precision medicine approach to genetic cardiomyopathy. Herz. 2017 Aug;42(5):468–475.
   PubMed Web of Science ®Google Scholar
• McNally EM. Mestroni L. Dilated Cardiomyopathy. Circ Res. 2017;121(7):731–748.
   PubMed Web of Science ®Google Scholar
• Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016 Jun;37(23):1850–1858.
   PubMed Web of Science ®Google Scholar
• Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet. 2017 Jul;390(10092):400–414.
   PubMed Web of Science ®Google Scholar
• Burke MA, Cook SA, Seidman JG, et al. Clinical and mechanistic insights into the genetics of cardiomyopathy. J Am Coll Cardiol. 2016 Dec;68(25):2871–2886.
   PubMed Web of Science ®Google Scholar
• Medizin S, Gmbh V, Heidelberg C. Precision medicine approach to genetic cardiomyopathy. Herz. 2017;42:468–475.
   PubMed Web of Science ®Google Scholar
• Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010 Apr;121(13):1533–1541.
   PubMed Web of Science ®Google Scholar
• Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol. 2012 Nov;60(20):2092–2099.
   PubMedGoogle Scholar
• Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004 Sep;292(11):1341–1344.
   PubMed Web of Science ®Google Scholar
• Skinner JR. Guidelines for the diagnosis and management of familial long QT syndrome. Heart Lung Circ. 2007 Feb;16(1):22–24.
   PubMedGoogle Scholar
• Etheridge SP, Compton SJ, Tristani-Firouzi M, et al. A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations. J Am Coll Cardiol. 2003 Nov;42(10):1777–1782.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Windle JR, Hall WJ, et al. Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol. 2005 Oct;10(4 Suppl):59–66.
   PubMed Web of Science ®Google Scholar
• Priori SG, Napolitano C, Schwartz PJ, et al. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation. 2000 Aug;102(9):945–947.
   PubMed Web of Science ®Google Scholar
• Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol. 2016 Mar;67(9):1053–1058.
   PubMed Web of Science ®Google Scholar
• Wang DW, Crotti L, Shimizu W, et al. Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel. Circ Arrhythm Electrophysiol. 2008 Dec;1(5):370–378.
   PubMed Web of Science ®Google Scholar
• Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary. Circulation. 2018 Sep;138(13):e210–71.
   PubMed Web of Science ®Google Scholar
• Cho Y. Left cardiac sympathetic denervation: an important treatment option for patients with hereditary ventricular arrhythmias. J Arrhythmia. 2016 Oct;32(5):340–343.
   PubMed Web of Science ®Google Scholar
• Collura CA, Johnson JN, Moir C, et al. Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. Hear Rhythm. 2009 6;Jun(6):752–759.
   Google Scholar
• Weatherford DA, Stephenson JE, Taylor SM, et al. Thoracoscopy versus thoracotomy: indications and advantages. Am Surg. 1995 Jan;61(1):83–86.
   PubMed Web of Science ®Google Scholar
• Woosley R, Heise C, Gallo T, et al. www.CredibleMeds.org, QTdrugs List. AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755.
   Google Scholar
• Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2013 Jan;61(3):e6–75.
   PubMed Web of Science ®Google Scholar
• Andorin A, Gourraud J-B, Mansourati J, et al. The QUIDAM study: hydroquinidine therapy for the management of Brugada syndrome patients at high arrhythmic risk. Hear Rhythm. 2017 Aug;14(8):1147–1154.
   PubMed Web of Science ®Google Scholar
• Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004 Sep;110(13):1731–1737.
   PubMed Web of Science ®Google Scholar
• Fisher JD, Krikler D, Hallidie-Smith KA. Familial polymorphic ventricular arrhythmias: A quarter century of successful medical treatment based on serial exercise-pharmacologic testing. J Am Coll Cardiol [Internet]. 1999;34(7):2015–2022. Available from: http://www.sciencedirect.com/science/article/pii/S0735109799004386
   PubMed Web of Science ®Google Scholar
• Sumitomo N, Harada K, Nagashima M, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 2003 Jan;89(1):66–70.
   PubMed Web of Science ®Google Scholar
• Rosso R, Kalman JM, Rogowski O, et al. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Hear Rhythm. 2007 Sep;4(9):1149–1154.
   PubMed Web of Science ®Google Scholar
• Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol [Internet]. 2004;43(8):1494–1499. Available from: http://www.sciencedirect.com/science/article/pii/S0735109704004437
   PubMed Web of Science ®Google Scholar
• Wolpert C, Schimpf R, Giustetto C, et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol [Internet]. 2005;16(1):54–58. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1540-8167.2005.04470.x
   PubMed Web of Science ®Google Scholar
• Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol [Internet]. 2011;58(6):587–595. Available from: http://www.sciencedirect.com/science/article/pii/S0735109711017748
   PubMed Web of Science ®Google Scholar
• Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy-a heart failure society of america practice guideline. J Card Fail. 2018 May;24(5):281–302.
   PubMed Web of Science ®Google Scholar
• Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011 Dec;58(25):e212–60.
   PubMed Web of Science ®Google Scholar
• Corrado D, Wichter T, Link MS, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Circulation. 2015 Aug;132(5):441–453.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med [Internet]. 2009;15(4):380–383.
   PubMed Web of Science ®Google Scholar
• van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011 May;57(22):2244–2254.
   PubMed Web of Science ®Google Scholar
• Watanabe H, van der Werf C, Roses-Noguer F, et al. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. Hear Rhythm. 2013 Apr;10(4):542–547.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Zareba W, Schwarz KQ, et al. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008 Dec;19(12):1289–1293.
   PubMed Web of Science ®Google Scholar
• Crotti L, Johnson CN, Graf E, et al. Calmodulin mutations associated with recurrent cardiac arrest in infants. Circulation. 2013 Mar;127(9):1009–1017.
   PubMed Web of Science ®Google Scholar
• Veerman CC, Mengarelli I, Guan K, et al. hiPSC-derived cardiomyocytes from Brugada Syndrome patients without identified mutations do not exhibit clear cellular electrophysiological abnormalities. Sci Rep. 2016;6:30967.
   PubMed Web of Science ®Google Scholar
• Liang P, Sallam K, Wu H, et al. Patient-specific and genome-edited induced pluripotent stem cell-derived cardiomyocytes elucidate single-cell phenotype of Brugada syndrome. J Am Coll Cardiol. 2016 Nov;68(19):2086–2096.
   PubMed Web of Science ®Google Scholar
• Bezzerides VJ, Caballero A, Wang S, et al. Gene therapy for catecholaminergic polymorphic ventricular tachycardia by inhibition of Ca(2+)/Calmodulin-dependent Kinase II. Circulation. 2019 Jul;140(5):405–419.
   PubMed Web of Science ®Google Scholar
• Ito R, Takahashi T, Ito M. Humanized mouse models: application to human diseases. J Cell Physiol. 2018 May;233(5):3723–3728.
   PubMed Web of Science ®Google Scholar
• Perlman RL. Mouse models of human disease: an evolutionary perspective. Evol Med public Heal. 2016;2016(1):170–176.
   PubMedGoogle Scholar
• Gomaa AA, Klumpe HE, Luo ML, et al. Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. MBio [Internet]. 2014 Jan 28;5(1):e00928. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24473129
   PubMed Web of Science ®Google Scholar
• Xie F, Ye L, Chang JC, et al. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res [Internet]. 2014 Sep;24(9):1526–1533. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25096406
   PubMed Web of Science ®Google Scholar
• Khan FA, Pandupuspitasari NS, Chun-Jie H, et al. CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases. Oncotarget [Internet]. 2016 Aug 9;7(32):52541–52552. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27250031
   PubMed Web of Science ®Google Scholar